Royce & Associates’s Fortress Biotech FBIO Stock Holding History

Royce & Associates’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-9,827	Closed	-$397K	–	1087
2016 Q2	$397K	Hold	9,827	–	–	﹤0.01%	1013
2016 Q1	$457K	Hold	9,827	–	–	﹤0.01%	991
2015 Q4	$411K	Hold	9,827	–	–	﹤0.01%	1032
2015 Q3	$383K	Hold	9,827	–	–	﹤0.01%	1066
2015 Q2	$495K	Sell	9,827 -5,800	-37%	-$298K	﹤0.01%	1086
2015 Q1	$902K	Sell	15,627 -15,533	-50%	-$647K	﹤0.01%	1032
2014 Q4	$1.14M	Sell	31,160 -4,173	-12%	-$123K	﹤0.01%	1054
2014 Q3	$1.11M	Hold	35,333	–	–	﹤0.01%	1110
2014 Q2	$912K	Hold	35,333	–	–	﹤0.01%	1155
2014 Q1	$1.05M	Hold	35,333	–	–	﹤0.01%	1148
2013 Q4	$1.39M	Buy	+35,333	New	+$1.36M	﹤0.01%	1125

Other funds holding FBIO

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BGA

Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Royce & Associates's FBIO Position: Q3 2016 in Review

Royce & Associates sold out of Fortress Biotech (FBIO) in Q3 2016, closing a stake of 9,827 shares — an estimated $397K sold.

Royce & Associates first reported a position in FBIO in Q4 2013 and held it in 11 quarters. The position peaked at $1.39M in Q4 2013. 50 funds tracked by Wall St. Rank hold FBIO as of Q3 2016.

Royce & Associates reported no remaining Fortress Biotech position as of Q3 2016 after selling out during the quarter.
Royce & Associates sold 9,827 Fortress Biotech shares in Q3 2016, an estimated $397K.
Royce & Associates first reported a position in Fortress Biotech in Q4 2013 and held it in 11 quarters.
Royce & Associates's Fortress Biotech position peaked at $1.39M in Q4 2013.
50 funds tracked by Wall St. Rank held Fortress Biotech as of Q3 2016.

Based on Royce & Associates's 13F filing for Q3 2016, filed 14 Nov 2016.